An in situ depot for the sustained release of a TLR7/8 agonist in combination with a TGFβ inhibitor promotes anti-tumor immune responses
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
1 Online-Ressource.
- Sprache
-
Englisch
- Erschienen in
-
An in situ depot for the sustained release of a TLR7/8 agonist in combination with a TGFβ inhibitor promotes anti-tumor immune responses ; volume:15 ; number:1 ; day:3 ; month:9 ; year:2024 ; pages:1-18 ; date:12.2024
Nature Communications ; 15, Heft 1 (3.9.2024), 1-18, 12.2024
- Klassifikation
-
Medizin, Gesundheit
- Urheber
-
Jensen, Sophie B.
Jæhger, Ditte E.
Serrano-Chávez, Elizabeth
Halldórsdóttir, Hólmfríður R.
Engel, Trine B.
Jørgensen, Jennifer S.
Björgvinsdóttir, Unnur J.
Kostrikov, Serhii
Scheeper, Marouschka J.
Ringgaard, Lars
Bruun, Linda M.
Stavnsbjerg, Camilla
Christensen, Esben
Bak, Martin
Thuroczy, Julianna
Balogh, Lajos
Jensen, Andreas T. I.
Melander, Fredrik
Kjaer, Andreas
Henriksen, Jonas R.
Hansen, Anders E.
Andresen, Thomas L.
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1038/s41467-024-50967-w
- URN
-
urn:nbn:de:101:1-2411261054217.563749275501
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:30 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Jensen, Sophie B.
- Jæhger, Ditte E.
- Serrano-Chávez, Elizabeth
- Halldórsdóttir, Hólmfríður R.
- Engel, Trine B.
- Jørgensen, Jennifer S.
- Björgvinsdóttir, Unnur J.
- Kostrikov, Serhii
- Scheeper, Marouschka J.
- Ringgaard, Lars
- Bruun, Linda M.
- Stavnsbjerg, Camilla
- Christensen, Esben
- Bak, Martin
- Thuroczy, Julianna
- Balogh, Lajos
- Jensen, Andreas T. I.
- Melander, Fredrik
- Kjaer, Andreas
- Henriksen, Jonas R.
- Hansen, Anders E.
- Andresen, Thomas L.
- SpringerLink (Online service)
Ähnliche Objekte (12)
Deoxyguanosine is a TLR7 agonist
Intratumoral delivery of TransCon™ TLR7/8 Agonist promotes sustained anti-tumor activity and local immune cell activation while minimizing systemic cytokine induction
Gastric cancer vaccines synthesized using a TLR7 agonist and their synergistic antitumor effects with 5-fluorouracil
Intratumoral immunotherapy with the TLR7/8 agonist 3M-052
TLR7 agonist, DSP-0509, with radiation combination therapy enhances anti-tumor activity and modulates T cell dependent immune activation
The TLR7 agonist Imiquimod promote the immunogenicity of msenchymal stem cells
Migrationsverhalten von NK-Zellen nach Stimulation mit dem TLR7-Agonisten Resiquimod
A combination of a TLR7/8 agonist and an epigenetic inhibitor suppresses triple-negative breast cancer through triggering anti-tumor immune
Lignin-chitosan-based biocomposite film for the localized delivery of TLR7 agonist imiquimod
T cell-independent eradication of experimental glioma by intravenous TLR7/8-agonist-loaded nanoparticles
Whole blood targeting and activation of monocytes with TLR7 agonist formulated in cationic liposomes
Persistent mutation burden drives sustained anti-tumor immune responses
Deoxyguanosine is a TLR7 agonist
Intratumoral delivery of TransCon™ TLR7/8 Agonist promotes sustained anti-tumor activity and local immune cell activation while minimizing systemic cytokine induction
Gastric cancer vaccines synthesized using a TLR7 agonist and their synergistic antitumor effects with 5-fluorouracil
Intratumoral immunotherapy with the TLR7/8 agonist 3M-052
TLR7 agonist, DSP-0509, with radiation combination therapy enhances anti-tumor activity and modulates T cell dependent immune activation
The TLR7 agonist Imiquimod promote the immunogenicity of msenchymal stem cells
Migrationsverhalten von NK-Zellen nach Stimulation mit dem TLR7-Agonisten Resiquimod
A combination of a TLR7/8 agonist and an epigenetic inhibitor suppresses triple-negative breast cancer through triggering anti-tumor immune
Lignin-chitosan-based biocomposite film for the localized delivery of TLR7 agonist imiquimod
T cell-independent eradication of experimental glioma by intravenous TLR7/8-agonist-loaded nanoparticles
Whole blood targeting and activation of monocytes with TLR7 agonist formulated in cationic liposomes
Persistent mutation burden drives sustained anti-tumor immune responses
Deoxyguanosine is a TLR7 agonist
Intratumoral delivery of TransCon™ TLR7/8 Agonist promotes sustained anti-tumor activity and local immune cell activation while minimizing systemic cytokine induction
Gastric cancer vaccines synthesized using a TLR7 agonist and their synergistic antitumor effects with 5-fluorouracil
Intratumoral immunotherapy with the TLR7/8 agonist 3M-052
TLR7 agonist, DSP-0509, with radiation combination therapy enhances anti-tumor activity and modulates T cell dependent immune activation
The TLR7 agonist Imiquimod promote the immunogenicity of msenchymal stem cells
Migrationsverhalten von NK-Zellen nach Stimulation mit dem TLR7-Agonisten Resiquimod
A combination of a TLR7/8 agonist and an epigenetic inhibitor suppresses triple-negative breast cancer through triggering anti-tumor immune
Lignin-chitosan-based biocomposite film for the localized delivery of TLR7 agonist imiquimod
T cell-independent eradication of experimental glioma by intravenous TLR7/8-agonist-loaded nanoparticles
Whole blood targeting and activation of monocytes with TLR7 agonist formulated in cationic liposomes